As Targeted Therapies Evolve, Challenges Remain

نویسندگان

چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pediatric MLBL: challenges remain.

In this issue of Blood, Gerrard et al report the outcome and histologic classification of children and adolescents with mediastinal large B-cell lymphoma (MLBL), and highlight the need for new treatment strategies.

متن کامل

Targeted Therapies in Breast Cancer: New Approaches and Old Challenges.

proaches interacting with growth factor signaling pathways that lead to estrogen receptor activation. Currently, we are experiencing relevant progress in endocrine therapy through approaches interacting with these signaling pathways, and several compounds will become available for clinical use within the next years. However, despite the fact that several compounds which target mTOR, PI3K, or CD...

متن کامل

Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer

Disclosures: Richard L. Schilsky: None; Jeff Allen: None; Joshua Benner: None; Ellen Sigal: None; Mark McClellan: None. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer review...

متن کامل

Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer

Lung cancer is difficult to treat with a poor prognosis and a five year survival of 15%. Current molecularly targeted therapies are initially effective in non-small cell lung cancer (NSCLC) patients; however, they are plagued with difficulties including induced resistance and small therapeutically responsive populations. This mini review describes the mechanism of resistance to several molecula...

متن کامل

Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma

Glioblastoma (GBM) is considered one of the most malignant, genetically heterogeneous, and therapy-resistant solid tumor. Therapeutic options are limited in GBM and involve surgical resection followed by chemotherapy and/or radiotherapy. Adjuvant therapies, including antiangiogenic treatments (AATs) targeting the VEGF-VEGFR pathway, have witnessed enhanced infiltration of bone marrow-derived my...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: JNCI Journal of the National Cancer Institute

سال: 2004

ISSN: 0027-8874,1460-2105

DOI: 10.1093/jnci/96.5.351